Schedule an appointment
Scott & Christie Eyecare Associates Expands to Meet GrowingDemand for the EVO Visian ICL Procedure
Posted by: Scott and Christie Eyecare Associates in News
Pittsburgh, PA – (October 30th, 2024) – Scott & Christie Eyecare Associates announced today the expansion of its services to include EVO Visian® ICL, an innovative technology approved by the FDA, which corrects nearsightedness without the use of glasses or contact lenses. EVO is an ideal option for patients who do not prefer glasses or contact lenses and are not candidates for laser eye surgery.
Doctors Christopher M. Spearman and Hamza M. Pasha are two of the first doctors at Scott & Christie Eyecare Associates to offer the procedure to patients. Both Dr. Spearman and Dr. Pasha bring a wealth of expertise to the community, specializing in a range of surgical procedures that address both common and complex eye conditions.
EVO ICL is an implantable lens positioned just below the surface of the eye to correct nearsightedness (both myopia and myopia with astigmatism). The procedure was designed to be more comfortable for the patient than earlier versions of the Visian ICL and a faster, more efficient procedure for surgeons than traditional laser surgeries. The EVO ICL is indicated for patients with a prescription between -3.0 up and -20.0 D, and can be used to treat astigmatism from 1.0 D to 4.0 D.
“The EVO ICL lens represents a significant advancement in our ability to correct nearsightedness and astigmatism,” said Dr. Hamza Pasha of Scott & Christie Eyecare Associates. “This enhanced version offers visual clarity, accommodating prescriptions that are double the safety threshold for LASIK. Importantly,
it avoids the risk of dry eye and is reversible, if needed.”
“We’re eager to introduce the new EVO lens at Scott & Christie Eyecare Associates, reinforcing our commitment to providing the highest quality vision correction for our patients,” said Dr. Christopher Spearman of Scott & Christie Eyecare Associates. “With this simple one-step surgery, our patients can correct nearsightedness and astigmatism without the need for laser procedures.”
Myopia, commonly known as nearsightedness, is the most common vision problem in the world, affecting approximately 1.9 billion people. This number is estimated to increase by 50 percent by the year 2050. To learn more about EVO Visian® ICL, visit https://us.discovericl.com/.
